LT3285772T - Specifinis trifluoroetilkinolino analogas, naudojamas sjögreno sindromo gydymui - Google Patents

Specifinis trifluoroetilkinolino analogas, naudojamas sjögreno sindromo gydymui

Info

Publication number
LT3285772T
LT3285772T LTEP16719356.4T LT16719356T LT3285772T LT 3285772 T LT3285772 T LT 3285772T LT 16719356 T LT16719356 T LT 16719356T LT 3285772 T LT3285772 T LT 3285772T
Authority
LT
Lithuania
Prior art keywords
sjögren
trifluoroethyl
syndrome
treatment
specific
Prior art date
Application number
LTEP16719356.4T
Other languages
English (en)
Inventor
Rodger Anthony Allen
Francesca BARONE
William Anthony FAHY
Saba NAYAR
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of LT3285772T publication Critical patent/LT3285772T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LTEP16719356.4T 2015-04-21 2016-04-20 Specifinis trifluoroetilkinolino analogas, naudojamas sjögreno sindromo gydymui LT3285772T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1506786.1A GB201506786D0 (en) 2015-04-21 2015-04-21 Therapeutic use
PCT/EP2016/058810 WO2016170014A1 (en) 2015-04-21 2016-04-20 A specific trifluoroethyl quinoline analogue for use in the treatment of sjögren's syndrome

Publications (1)

Publication Number Publication Date
LT3285772T true LT3285772T (lt) 2020-01-10

Family

ID=53298950

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16719356.4T LT3285772T (lt) 2015-04-21 2016-04-20 Specifinis trifluoroetilkinolino analogas, naudojamas sjögreno sindromo gydymui

Country Status (27)

Country Link
US (1) US10493074B2 (lt)
EP (1) EP3285772B1 (lt)
JP (1) JP6721606B2 (lt)
KR (1) KR102627370B1 (lt)
CN (1) CN107530344B (lt)
AR (1) AR105552A1 (lt)
AU (1) AU2016251236B2 (lt)
BR (1) BR112017020591B8 (lt)
CA (1) CA2981631C (lt)
CL (1) CL2017002669A1 (lt)
CO (1) CO2017010573A2 (lt)
CY (1) CY1122572T1 (lt)
DK (1) DK3285772T3 (lt)
EA (1) EA032432B1 (lt)
ES (1) ES2763335T3 (lt)
GB (1) GB201506786D0 (lt)
HR (1) HRP20192273T1 (lt)
HU (1) HUE047162T2 (lt)
IL (1) IL254766B (lt)
LT (1) LT3285772T (lt)
MX (1) MX2017013148A (lt)
MY (1) MY192972A (lt)
PL (1) PL3285772T3 (lt)
PT (1) PT3285772T (lt)
SG (1) SG11201707789YA (lt)
SI (1) SI3285772T1 (lt)
WO (1) WO2016170014A1 (lt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201708856D0 (en) 2017-06-02 2017-07-19 Ucb Biopharma Sprl Seletalisib crystalline forms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2605792T3 (es) * 2004-05-13 2017-03-16 Icos Corporation Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
UA98955C2 (ru) * 2007-03-23 2012-07-10 Амген Инк. Гетероциклические соединения и их применение
AP2012006294A0 (en) * 2009-11-05 2012-06-30 Rhizen Pharmaceuticals Sa Novel kinase modulators.
UA112517C2 (uk) * 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
AR082799A1 (es) * 2010-09-08 2013-01-09 Ucb Pharma Sa Derivados de quinolina y quinoxalina como inhibidores de quinasa
NZ714710A (en) * 2013-06-14 2016-11-25 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors

Also Published As

Publication number Publication date
CY1122572T1 (el) 2021-01-27
JP6721606B2 (ja) 2020-07-15
BR112017020591B8 (pt) 2023-05-16
BR112017020591A2 (pt) 2018-07-03
AR105552A1 (es) 2017-10-18
HUE047162T2 (hu) 2020-04-28
EA032432B1 (ru) 2019-05-31
EP3285772A1 (en) 2018-02-28
IL254766A0 (en) 2017-12-31
CN107530344B (zh) 2020-03-17
PL3285772T3 (pl) 2020-05-18
CO2017010573A2 (es) 2018-03-09
CL2017002669A1 (es) 2018-05-11
CA2981631A1 (en) 2016-10-27
KR20170140245A (ko) 2017-12-20
US20180092921A1 (en) 2018-04-05
WO2016170014A1 (en) 2016-10-27
DK3285772T3 (da) 2020-01-13
BR112017020591B1 (pt) 2023-02-07
AU2016251236B2 (en) 2018-06-14
CA2981631C (en) 2023-02-21
EP3285772B1 (en) 2019-10-02
HRP20192273T1 (hr) 2020-03-06
EA201792318A1 (ru) 2018-05-31
CN107530344A (zh) 2018-01-02
SG11201707789YA (en) 2017-11-29
ES2763335T3 (es) 2020-05-28
IL254766B (en) 2020-05-31
KR102627370B1 (ko) 2024-01-18
GB201506786D0 (en) 2015-06-03
MY192972A (en) 2022-09-20
AU2016251236A1 (en) 2017-11-09
SI3285772T1 (sl) 2020-02-28
JP2018513862A (ja) 2018-05-31
MX2017013148A (es) 2018-02-21
US10493074B2 (en) 2019-12-03
PT3285772T (pt) 2020-01-14

Similar Documents

Publication Publication Date Title
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
IL247841B (en) Heterocyclic compounds in combination with immune barrier therapy for use in the treatment of disorders mediated by pi3k gamma
IL262943A (en) A specific trifluoroethyl quinoline analogue for use in the treatment of apds
IL251904B (en) Epilimod for use in the treatment of melanoma
IL249402A0 (en) Aminoglycosides for the treatment of Rett's syndrome
EP3154488A4 (en) Absorbent article exhibiting controlled deformation in use
IL247969B (en) A medicinal component for use in the treatment of infections
IL252174A0 (en) Quinoline carboxamides for use in the treatment of leukemia
HUE039750T2 (hu) Hidroxi-buspiron mozgászavarok kezelésére
EP3238600A4 (en) Adhesive cleaner for use in antibacterial treatment
IL251840A0 (en) Use of femiroplast in the treatment of severe asthma
HK1217913A1 (zh) 阿地米屈在治療上皮功能障礙中的用途
EP3154487A4 (en) Absorbent article exhibiting controlled deformation in use
LT3285772T (lt) Specifinis trifluoroetilkinolino analogas, naudojamas sjögreno sindromo gydymui
PL3229780T3 (pl) Kompozycje okulistyczne do zastosowania w leczeniu zespołu suchego oka
IL247207A0 (en) Use of pericalcitol in the treatment of inflammatory anemia
GB201418541D0 (en) Materials for use with general hyperthermia treatment
EP3305300C0 (en) INTRAVITREAL LYSINE ACETYL SALICYLATE FOR USE IN TREATING DIABETIC RETINOPATHY
ZA201408464B (en) Composition for the use in treatment of asthma
GB201407244D0 (en) Apparatus for use in the manufacture of glass items
GB201419839D0 (en) Finger dressing
GB201416493D0 (en) Polypeptides for use in therapy
GB201409978D0 (en) Novel compounds and their use in therapy